Please provide your email address to receive an email when new articles are posted on . LOUISVILLE, Ky. — Patients with asthma had a greater risk for ischemic heart disease compared with those without ...

In many patients, annual short-acting beta2-agonist prescription fulfillment is indicative of uncontrolled disease and increased incidence of exacerbations. Credit: Getty Images. Short-acting beta ...

Please provide your email address to receive an email when new articles are posted on . High FeNO levels indicate exacerbation and lung function risks. Most patients with high FeNO levels also had ...

As-needed use of albuterol–budesonide has been shown to result in a significantly lower risk of severe asthma exacerbation than as-needed use of albuterol alone among patients with moderate-to-severe ...

This transcript has been edited for clarity. Michael Wechsler, MD: Hi. I’m Dr Mike Wechsler and welcome to Medscape’s InDiscussion series on moderate to severe asthma. This is episode one of the first ...

For decades, scientists have thought they understood the biochemical machinery that causes asthma—inflammation in the lungs ...

The inclusion of BATURA study results in the US prescribing information builds upon the previous MANDALA Phase III trial in adult patients with moderate to severe asthma. 3 The MANDALA and BATURA ...

Three abstracts evaluating dupilumab (Dupixent) for moderate-to-severe asthma were presented at the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting: VESTIGE, a phase IV ...

Individuals with severe asthma have elevated concentrations of CSF neurogranin and amplification of synaptic degeneration associated with cardiovascular risk. Patients with severe asthma have ...

In October, AstraZeneca revealed that early results from a phase 3 trial of its dual-drug asthma inhaler Airsupra were so convincing that an independent committee decided to halt the study based on ...